[go: up one dir, main page]

FR2793414B1 - Conjugue acide nucleique-anticorps pour delivrer un acide nucleique etranger dans les cellules - Google Patents

Conjugue acide nucleique-anticorps pour delivrer un acide nucleique etranger dans les cellules

Info

Publication number
FR2793414B1
FR2793414B1 FR9905943A FR9905943A FR2793414B1 FR 2793414 B1 FR2793414 B1 FR 2793414B1 FR 9905943 A FR9905943 A FR 9905943A FR 9905943 A FR9905943 A FR 9905943A FR 2793414 B1 FR2793414 B1 FR 2793414B1
Authority
FR
France
Prior art keywords
nucleic acid
cells
antibody conjugate
delivering foreign
foreign nucleic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9905943A
Other languages
English (en)
Other versions
FR2793414A1 (fr
Inventor
Francois Hirsch
Antoine Durrbach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR9905943A priority Critical patent/FR2793414B1/fr
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Priority to JP2000616728A priority patent/JP2002543810A/ja
Priority to CA002373851A priority patent/CA2373851A1/fr
Priority to IL14639900A priority patent/IL146399A0/xx
Priority to AU44152/00A priority patent/AU4415200A/en
Priority to PCT/FR2000/001259 priority patent/WO2000067697A2/fr
Priority to EP00925426A priority patent/EP1175498A2/fr
Publication of FR2793414A1 publication Critical patent/FR2793414A1/fr
Application granted granted Critical
Publication of FR2793414B1 publication Critical patent/FR2793414B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038Kidney, bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6861Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from kidney or bladder cancer cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Physical Education & Sports Medicine (AREA)
FR9905943A 1999-05-10 1999-05-10 Conjugue acide nucleique-anticorps pour delivrer un acide nucleique etranger dans les cellules Expired - Fee Related FR2793414B1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
FR9905943A FR2793414B1 (fr) 1999-05-10 1999-05-10 Conjugue acide nucleique-anticorps pour delivrer un acide nucleique etranger dans les cellules
CA002373851A CA2373851A1 (fr) 1999-05-10 2000-05-10 Conjugue acide nucleique-anticorps pour delivrer un acide nucleique etranger dans les cellules
IL14639900A IL146399A0 (en) 1999-05-10 2000-05-10 Nucleic acid-antibody conjugate for delivering a foreign nucleic acid in cells
AU44152/00A AU4415200A (en) 1999-05-10 2000-05-10 Nucleic acid-antibody conjugate for delivering a foreign nucleic acid in cells
JP2000616728A JP2002543810A (ja) 1999-05-10 2000-05-10 外来性核酸を細胞に送達するための核酸−抗体複合体
PCT/FR2000/001259 WO2000067697A2 (fr) 1999-05-10 2000-05-10 Conjugue acide nucleique-anticorps pour delivrer un acide nucleique etranger dans les cellules
EP00925426A EP1175498A2 (fr) 1999-05-10 2000-05-10 Conjugue acide nucleique-anticorps pour delivrer un acide nucleique etranger dans les cellules

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9905943A FR2793414B1 (fr) 1999-05-10 1999-05-10 Conjugue acide nucleique-anticorps pour delivrer un acide nucleique etranger dans les cellules

Publications (2)

Publication Number Publication Date
FR2793414A1 FR2793414A1 (fr) 2000-11-17
FR2793414B1 true FR2793414B1 (fr) 2003-05-23

Family

ID=9545418

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9905943A Expired - Fee Related FR2793414B1 (fr) 1999-05-10 1999-05-10 Conjugue acide nucleique-anticorps pour delivrer un acide nucleique etranger dans les cellules

Country Status (7)

Country Link
EP (1) EP1175498A2 (fr)
JP (1) JP2002543810A (fr)
AU (1) AU4415200A (fr)
CA (1) CA2373851A1 (fr)
FR (1) FR2793414B1 (fr)
IL (1) IL146399A0 (fr)
WO (1) WO2000067697A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006517793A (ja) * 2003-01-31 2006-08-03 ノバルティス アクチエンゲゼルシャフト スクリーニングアッセイ
JP4521519B2 (ja) * 2003-05-26 2010-08-11 学校法人慶應義塾 部分ヒストンテイル型イムノポーター
FR2958645B1 (fr) * 2010-04-09 2012-08-31 Commissariat Energie Atomique Hemi-anticorps a auto-assemblage
US10540907B2 (en) 2014-07-31 2020-01-21 Intelligent Technologies International, Inc. Biometric identification headpiece system for test taking
WO2016028864A1 (fr) 2014-08-22 2016-02-25 Intelligent Technologies International, Inc. Dispositif, système et procédé de test sûr
US10410535B2 (en) 2014-08-22 2019-09-10 Intelligent Technologies International, Inc. Secure testing device
WO2016073202A1 (fr) 2014-11-04 2016-05-12 Intelligent Technologies International, Inc. Carte intelligente
CN108530540B (zh) * 2018-03-30 2021-06-15 华南农业大学 抗亚精胺单克隆抗体杂交瘤细胞株4e4及其单克隆抗体和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166320A (en) * 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
EP0366707A1 (fr) * 1987-05-06 1990-05-09 OOSTERWIJK, Egbert Anticorps monoclonaux contre le carcinome des cellules renales
US5428132A (en) * 1987-10-11 1995-06-27 United States Of America Conjugate and method for integration of foreign DNA into cells
IL106760A (en) * 1992-08-25 1999-12-31 Miles Inc Nuclear Acid Protein Hybrid Structure for Transferring Nucleic Acid from External Source to Cell and Target Nucleus
US5574142A (en) * 1992-12-15 1996-11-12 Microprobe Corporation Peptide linkers for improved oligonucleotide delivery
IL112372A (en) * 1994-02-07 2001-08-26 Res Dev Foundation Non-viral vector for the delivery of genetic information to cells
NZ295673A (en) * 1994-11-01 1999-03-29 Wels Wilfried Nucleic acid transfer system using recombinant multi-domain proteins each domain having a different function
GB9614699D0 (en) * 1996-07-12 1996-09-04 John P Robarts Research Inst T Hybrid herpes virus-based vector for gene delivery and expression
DE19717904A1 (de) * 1997-04-23 1998-10-29 Diagnostikforschung Inst Säurelabile und enzymatisch spaltbare Farbstoffkonstrukte zur Diagnostik mit Nahinfrarotlicht und zur Therapie
JP2002511857A (ja) * 1997-06-11 2002-04-16 ザ スクール オブ ファーマシー ユニヴァーシティ オブ ロンドン 抗体−酵素複合体をプロドラッグと組合せて含む薬学的組成物

Also Published As

Publication number Publication date
WO2000067697A2 (fr) 2000-11-16
WO2000067697A3 (fr) 2001-06-28
FR2793414A1 (fr) 2000-11-17
EP1175498A2 (fr) 2002-01-30
JP2002543810A (ja) 2002-12-24
CA2373851A1 (fr) 2000-11-16
AU4415200A (en) 2000-11-21
IL146399A0 (en) 2002-07-25

Similar Documents

Publication Publication Date Title
EP1203008A4 (fr) Ligands acide nucleique reactifs vis-a-vis de ligand cd40
EP1176986A4 (fr) Differentiation de monocytes transformes en cellules dendritiques fonctionnelles
IT1293509B1 (it) Addensanti per composizioni acquose acide
FR2763943B1 (fr) Composes, leur preparation et leur utilisation pour le transfert d'acides nucleiques dans les cellules
NO20015828D0 (no) Fremgangsmåter for fremstilling av 5'-nukleinsyre- proteinkonjugater
FR2798037B1 (fr) Cultivateur pour la culture du sol
FR2793414B1 (fr) Conjugue acide nucleique-anticorps pour delivrer un acide nucleique etranger dans les cellules
CY2010007I1 (el) Προσδιορισμος in vivo δια την δοκιμασιαν της φαινοτυπικης σταθepοτητος
EP1225224A4 (fr) Adn reagissant a la contrainte de cisaillement
FR2798939B1 (fr) Reduction du cokage dans les reacteurs de craquage
IT1295355B1 (it) Addensanti per composizioni acquose acide
FR2791673B1 (fr) Procede de preparation des esters de l'acide hydroxymethylthiobutyrique
EP1963514A4 (fr) Procedes pour la transfection d'acides nucleiques dans des cellules vivantes
FR2769855B1 (fr) Compositions destinees a la culture en sol de fertilite reduite
EP1250156A4 (fr) Methodes de transfection cellulaire par introduction d'acide nucleique
FR2765482B1 (fr) Utilisation de l'acide y-linolenique pour prevenir le stress oxydatif
FR2798826B1 (fr) Filtre pour narguile
FR2814370B1 (fr) Utilisation d'un complexe acide nucleique/pei pour le ciblage de cellules souches du cerveau
EP1252818A4 (fr) Methode de transfert d'adn mitochondrial mutant dans des cellules de reproduction
EP1003849A4 (fr) Procede pour attenuer la variabilite de l'expression des transgenes dans les cellules vegetales
GB2351516B (en) Improvements relating to piles
HK1047131A1 (zh) 一種將抗原轉移到樹突狀細胞的方法
FR2807642B1 (fr) Ameliorations introduites dans les catheters pour l'insemination artificielle des lapines
EP1155115A4 (fr) Procede de modification pour cellules cytotoxiques et utilisations correspondantes
GB2355437B (en) Improvements relating to anchorages

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20160129